$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000101749116000164 Filed on May 09, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$626.0K	$475.0K
YoY Change	31.79%
Cost Of Revenue	$233.0K	$233.0K
YoY Change	0.0%
Gross Profit	$393.0K	$242.0K
YoY Change	62.4%
Gross Profit Margin	62.78%	50.95%
Selling, General & Admin	$2.220M	$3.100M
YoY Change	-28.39%	1.31%
% of Gross Profit	564.89%	1280.99%
Research & Development	$2.602M	$3.268M
YoY Change	-20.38%	126.32%
% of Gross Profit	662.09%	1350.41%
Depreciation & Amortization	$72.00K	$74.00K
YoY Change	-2.7%	270.0%
% of Gross Profit	18.32%	30.58%
Operating Expenses	$4.826M	$6.364M
YoY Change	-24.17%	79.62%
Operating Profit	-$4.826M	-$6.122M
YoY Change	-21.17%	72.79%
Interest Expense	-$279.0K	-$158.0K
YoY Change	76.58%	47.66%
% of Operating Profit
Other Income/Expense, Net	$2.312M	-$290.0K
YoY Change	-897.24%	-203.2%
Pretax Income	-$2.510M	-$6.410M
YoY Change	-60.84%	96.63%
Income Tax	$4.000K	$0.00
% Of Pretax Income
Net Earnings	-$2.505M	-$6.412M
YoY Change	-60.93%	96.57%
Net Earnings / Revenue	-400.16%	-1349.89%
Basic Earnings Per Share	-$0.46	-$0.13
Diluted Earnings Per Share	-$0.95	-$0.13
COMMON SHARES
Basic Shares Outstanding	5.505M shares	47.63M shares
Diluted Shares Outstanding	5.602M shares	47.63M shares

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.910M	$16.16M
YoY Change	-57.24%	-28.15%
Cash & Equivalents	$6.907M	$16.16M
Short-Term Investments
Other Short-Term Assets	$1.120M	$1.150M
YoY Change	-2.61%	85.48%
Inventory	$405.0K	$217.0K
Prepaid Expenses
Receivables	$688.0K	$513.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$9.119M	$18.04M
YoY Change	-49.44%	-23.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.235M	$1.449M
YoY Change	-14.77%	6.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$78.00K	$153.0K
YoY Change	-49.02%	64.52%
Total Long-Term Assets	$1.313M	$1.602M
YoY Change	-18.04%	10.25%
TOTAL ASSETS
Total Short-Term Assets	$9.119M	$18.04M
Total Long-Term Assets	$1.313M	$1.602M
Total Assets	$10.43M	$19.64M
YoY Change	-46.88%	-21.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.100M	$880.0K
YoY Change	25.0%	-11.11%
Accrued Expenses	$2.902M	$5.016M
YoY Change	-42.15%	153.46%
Deferred Revenue
YoY Change
Short-Term Debt	$8.750M	$530.0K
YoY Change	1550.94%	-80.08%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.25M	$7.158M
YoY Change	85.08%	-50.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$4.300M
YoY Change	-100.0%
Other Long-Term Liabilities	$179.0K	$302.0K
YoY Change	-40.73%	277.5%
Total Long-Term Liabilities	$179.0K	$302.0K
YoY Change	-40.73%	277.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.25M	$7.158M
Total Long-Term Liabilities	$179.0K	$302.0K
Total Liabilities	$17.28M	$17.97M
YoY Change	-3.85%	22.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$311.4M	-$296.3M
YoY Change	5.1%	9.19%
Common Stock	$304.5M	$297.9M
YoY Change	2.22%	6.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.843M	$1.670M
YoY Change
Total Liabilities & Shareholders Equity	$10.43M	$19.64M
YoY Change	-46.88%	-21.43%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$2.505M	-$6.412M
YoY Change	-60.93%	96.57%
Depreciation, Depletion And Amortization	$72.00K	$74.00K
YoY Change	-2.7%	270.0%
Cash From Operating Activities	-$6.122M	-$6.127M
YoY Change	-0.08%	3091.15%
INVESTING ACTIVITIES
Capital Expenditures	$6.000K	$165.0K
YoY Change	-96.36%	-53.52%
Acquisitions
YoY Change
Other Investing Activities	$100.0K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$6.000K	-$165.0K
YoY Change	-96.36%	-45.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$9.947M	$10.96M
YoY Change	-9.22%	567.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$9.148M	$11.05M
YoY Change	-17.2%	597.92%
NET CHANGE
Cash From Operating Activities	-$6.122M	-$6.127M
Cash From Investing Activities	-$6.000K	-$165.0K
Cash From Financing Activities	$9.148M	$11.05M
Net Change In Cash	$3.020M	$4.756M
YoY Change	-36.5%	337.94%
FREE CASH FLOW
Cash From Operating Activities	-$6.122M	-$6.127M
Capital Expenditures	$6.000K	$165.0K
Free Cash Flow	-$6.128M	-$6.292M
YoY Change	-2.61%	1050.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000.0	USD
CY2016Q1	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	5002000	USD
CY2016Q1	apri	License Fees Expected Future Proceeds LicenseFeesExpectedFutureProceeds	212661000	USD
CY2016Q1	apri	License Fees Expected Future Proceedson Commercial Launch Payments LicenseFeesExpectedFutureProceedsonCommercialLaunchPayments	27631000	USD
CY2016Q1	apri	License Fees Expected Future Proceedson Regulatory Milestones LicenseFeesExpectedFutureProceedsonRegulatoryMilestones	5353000	USD
CY2016Q1	apri	License Fees Expected Future Proceedson Sales Milestones LicenseFeesExpectedFutureProceedsonSalesMilestones	179677000	USD
CY2016Q1	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2016Q1	apri	Public Offering Ceiling Based On Current Public Float PublicOfferingCeilingBasedOnCurrentPublicFloat	21200000	USD
CY2015Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	2228000	USD
CY2016Q1	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	1420000	USD
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm	P2Y0M7D
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P3Y7M10D
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
CY2016Q1	dei	Trading Symbol TradingSymbol	APRI
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1580000	USD
CY2016Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1096000	USD
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P4Y11M7D
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1154
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	5815374	shares
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	4.07
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.88
CY2015Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.30
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.16
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	0.00
CY2016Q1	apri	Share Price Floor Price Required To Use Committed Equity Financing SharePriceFloorPriceRequiredToUseCommittedEquityFinancing	1.00
CY2016Q1	apri	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms	P6Y11M7D
CY2016Q1	apri	Shelf Registration Statement Amount Currently Reserved ShelfRegistrationStatementAmountCurrentlyReserved	18200000	USD
CY2016Q1	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	79000000	USD
CY2015Q1	apri	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2016Q1	apri	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	137000	USD
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61808619	shares
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	519000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	688000	USD
CY2015Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	58000	USD
CY2016Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	100000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1223000	USD
CY2016Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	405000	USD
CY2015Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6000	USD
CY2016Q1	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	3000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3343000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2902000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	466000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1086000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	298881000	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	304475000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	355000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	289000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	355000	USD
CY2015Q4	us-gaap	Assets Assets	7781000	USD
CY2016Q1	us-gaap	Assets Assets	10432000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	6217000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	9119000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000	USD
CY2015Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2016Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16156000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6907000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4756000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3020000	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14519169	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50414481	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61778121	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50414481	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61778121	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	62000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	233000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	233000	USD
CY2015Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	88000	USD
CY2016Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2015Q1	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	10000	USD
CY2016Q1	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	100000	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	135000	USD
CY2016Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	89000	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	178000	USD
CY2016Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	178000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	65000	USD
CY2016Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	90000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	137000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	99000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1841000	USD
CY2016Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3848000	USD
CY2016Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3800000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2015Q1	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2016Q1	us-gaap	Dilutive Securities DilutiveSecurities	-2595000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	136000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2595000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3096000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2404000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	242000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	393000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6412000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2501000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-68000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-374000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-165000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	169000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	461000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-589000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-562000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-569000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-45000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-39000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-58000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-64000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-23000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-55000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-20000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	223000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-123000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	200000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-158000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-279000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	469000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	405000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	145000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	86000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	324000	USD
CY2016Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	319000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	17725000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	17275000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7781000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10432000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15684000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13248000	USD
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	350000	USD
CY2016Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11048000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9148000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6127000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6122000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-6412000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-2505000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6412000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2505000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6412000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5100000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2316000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9401000	USD
CY2016Q1	us-gaap	Notes Payable Current NotesPayableCurrent	8746000	USD
CY2016Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	6364000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	5210000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6122000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4817000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	465000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	215000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	274000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	179000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	165000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1062000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	939000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10957000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9804000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7800000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1290000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1235000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1000	USD
CY2015Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	755000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3268000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2806000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	280000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	180000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308875000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311380000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	88000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	367000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	259000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	475000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	626000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	289000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	355000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0139
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0157
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55050000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	0	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5681818	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8837351	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	14519169	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	27437	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1502000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.05
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.76
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4053605	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5528168	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.95
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.71
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.89
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.11
CY2016Q1	us-gaap	Share Price SharePrice	0.58
CY2016Q1	us-gaap	Share Price SharePrice	1.35
CY2015Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016Q1	us-gaap	Stock Issued1 StockIssued1	249000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	249000	USD
CY2016Q1	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	5000000	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-9944000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	-6843000	USD
CY2015Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	971000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47633000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56021000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47633000	shares

Files In Submission

Name	View Source	Status
0001017491-16-000164-index-headers.html	Edgar Link	pending
0001017491-16-000164-index.html	Edgar Link	pending
0001017491-16-000164.txt	Edgar Link	pending
0001017491-16-000164-xbrl.zip	Edgar Link	pending
apri-20160331.xml	Edgar Link	completed
apri-20160331.xsd	Edgar Link	pending
apri-20160331_cal.xml	Edgar Link	unprocessable
apri-20160331_def.xml	Edgar Link	unprocessable
apri-20160331_lab.xml	Edgar Link	unprocessable
apri-20160331_pre.xml	Edgar Link	unprocessable
apri3311610q.htm	Edgar Link	pending
apri33116ex104.htm	Edgar Link	pending
apri33116ex105.htm	Edgar Link	pending
apri33116ex106.htm	Edgar Link	pending
apri33116ex107.htm	Edgar Link	pending
apri33116ex311.htm	Edgar Link	pending
apri33116ex312.htm	Edgar Link	pending
apri33116ex321.htm	Edgar Link	pending
apri33116ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2016 Q1 Form 10-Q Financial Statement

#000101749116000164 Filed on May 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2016 Q1 Form 10-Q Financial Statement

#000101749116000164 Filed on May 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel